


MEETING VENUE

Centro Servizi e Formazione Montedomini

Il Fuligno

Via Faenza 48

50122 Florence, Italy



<https://eestudygroup.com/>

Follow us on 

Scientific Chairmen

Giacomo Emmi
Benjamin Terrier
Augusto Vaglio

Faculty

Alvise Berti, *Italy*
Lara Bernardi, *Italy*
Alessandra Bettiol, *Italy*
Paolo Cameli, *Italy*
Marco Caminati, *Italy*
Edoardo Conticini, *Italy*
Vincent Cottin, *France*
Paolo Delvino, *Italy*
Eugenia Durante, *Italy*
Allyson Egan, *Ireland*
Giacomo Emmi, *Italy*
Francesco Ferro, *Italy*
Matthieu Groh, *France*
Loïc Guillevin, *France*
David Jackson, *UK*
Vieri Lastrucci, *Italy*
Davide Martorana, *Italy*
Irene Mattioli, *Italy*
Peter Merkel, *USA*
Aladdin Mohammad, *Sweden*
Sara Monti, *Italy*
Roberto Padoan, *Italy*
Julie Power, *Ireland*
Dario Roccatello, *Italy*
Florence Roufosse, *France*
Paul J Russo, *Australia*
Carlo Salvarani, *Italy*
Savino Sciascia, *Italy*
Salman Siddiqui, *UK*
Renato Alberto Sinico, *Italy*
Rona Smith, *UK*
Sara Talarico, *Italy*
Benjamin Terrier, *France*
Michelangelo Tesi, *Italy*
Francesca Torracca, *Italy*
Augusto Vaglio, *Italy*
Sam Whittle, *Australia*

Sponsor



Organizing Secretariat



Viale dei Mille, 137
50131 Firenze
Email: marta.bartoletti@eve-lab.it
Tel. 055 0671000
www.eve-lab.com

8th

MEETING OF THE EUROPEAN EGPA STUDY GROUP



**September
26th
2024**

FLORENCE

**Centro Servizi e Formazione Montedomini
Il Fuligno**

EGPA MEETING PROGRAM

FLORENCE

26

THURSDAY
SEPTEMBER

8.20 am Welcome and introduction
A. Vaglio, B. Terrier, G. Emmi

FIRST SESSION
PATIENT ADVOCACY ORGANIZATION
Chairmen: *A. Mohammad, A. Berti*

8.30 am Building an EGPA patient advocacy organization in Europe: practical steps
F. Torracca, E. Durante, President and Vice-president of the Italian EGPA association (APACS)

8.45 am Delegate from Vasculitis International
J. Power

9.00 am Delegate from pharma industry
L. Bernardi, GSK patient affairs

9.15 am Open discussion

9.30 am Lecture:
New treatments for severe asthma
D. Jackson
Introduction: *B. Terrier*

SECOND SESSION
ONGOING AND COMPLETED NON-PHARMACOLOGICAL STUDIES
Chairmen: *R. A. Sinico, A. Mohammad*

10.00 am Disease susceptibility and response to IL-5 blockade in patients with EGPA: an epigenome-wide association study integrated with transcriptomic and proteomic analyses
M. Tesi

10.10 am REACT score - Relapse in ANCA-associated vasculitis after Cyclophosphamide induction Therapy
V. Lastrucci

10.20 am Exome-Wide Association Study on familial and sporadic EGPA patients
D. Martorana

10.30 am Open discussion

10.45 am Coffee break

11.15 am Eosinophilia related temporal arteritis
B. Terrier

11.25 am Eosinophilic meningitis and NLRP3 mutations
M. Groh

11.35 am Impact of mepolizumab on AAV-PRO questionnaire in EGPA
P. Delvino

11.45 am The unmet needs in EGPA: experts' and patients' opinion
E. Conticini, P. Cameli

11.55 am Heart involvement in EGPA: a European collaborative study
S. Monti

12.05 pm Overall long-term follow-up and damage accrual in EGPA across Europe
A. Mohammad, R. Padoan

12.15 pm Pulmonary infiltrates in EGPA: not only eosinophilic pneumonia
F. Ferro

12.25 pm Development of a new disease activity score for EGPA
A. Bettiol, S. Talarico

12.40 pm Diagnostic criteria of EGPA
V. Cottin (online)

12.50 pm Open discussion

1.00 pm Lunch

GROUP PHOTO

2.00 pm Lecture:
Differential diagnosis in eosinophilic disorders
F. Roufosse
Introduction: *L. Guillevin*

THIRD SESSION
ONGOING AND COMPLETED PHARMACOLOGICAL STUDIES
Chairmen: *S. Siddiqui, C. Salvarani*

2.30 pm Efficacy and safety of JAK-inhibitors in EGPA
P. J Russo, S. Whittle (online)

2.40 pm Renal Involvement in Eosinophilic Granulomatosis with Polyangiitis
D. Roccatello, S. Sciascia

2.50 pm Mepolizumab vs. Benralizumab in EGPA: a retrospective comparative study
I. Mattioli

3.00 pm Effectiveness of Benralizumab after Mepolizumab treatment: an EESG and FVSG study
G. Emmi

3.10 pm Mepolizumab in EGPA: long-term follow-up and switching study
G. Emmi

3.20 pm The impact of BMI on the effectiveness of Mepolizumab in EGPA patients
A. Berti

3.30 pm The effectiveness and safety of mepolizumab 300 mg in newly diagnosed EGPA patients: the MEPEARL study
R. Padoan

3.40 pm Tezepelumab in EGPA: a retrospective observational study
B. Terrier

3.50 pm Mycophenolate mofetil remission induction and maintenance therapy in EGPA: a multicentre observational study
A. Egan

4.00 pm Targeting eosinophils in EGPA patients: benralizumab or mepolizumab? Highlights from the EESG datasets
M. Caminati

4.10 pm Open discussion

FOURTH SESSION
CLINICAL TRIALS AND REGISTRIES
Chairmen: *R. Smith, D. Jackson*

4.30 pm European study on eosinophil-associated diseases: the Cohesion project
M. Groh

4.45 pm A randomised placebo-controlled trial to explore the efficacy and mechanism of action of Tezepelumab in EGPA: The Racemate trial
S. Siddiqui

5.00 pm The Vasculitis Clinical Research Consortium (VCRC) and the JAK-inhibitors trial in EGPA
P. Merkel (online)

5.20 pm The FVSG Trials: an update
B. Terrier

5.35 pm The FAIRVASC project: building a federated EGPA registry in Europe
G. Emmi, A. Vaglio

5.50 pm Open discussion

Close
A. Vaglio, B. Terrier, G. Emmi